ZA201508782B - Method of treating disease by auricular anesthesia of cranial nerves - Google Patents

Method of treating disease by auricular anesthesia of cranial nerves

Info

Publication number
ZA201508782B
ZA201508782B ZA2015/08782A ZA201508782A ZA201508782B ZA 201508782 B ZA201508782 B ZA 201508782B ZA 2015/08782 A ZA2015/08782 A ZA 2015/08782A ZA 201508782 A ZA201508782 A ZA 201508782A ZA 201508782 B ZA201508782 B ZA 201508782B
Authority
ZA
South Africa
Prior art keywords
treating disease
cranial nerves
auricular anesthesia
auricular
anesthesia
Prior art date
Application number
ZA2015/08782A
Other languages
English (en)
Inventor
M Crews Thomas
Original Assignee
Thomas M Crews A American Citizen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas M Crews A American Citizen filed Critical Thomas M Crews A American Citizen
Publication of ZA201508782B publication Critical patent/ZA201508782B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0046Ear
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245Amino benzoic acid types, e.g. procaine, novocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41521,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA2015/08782A 2013-05-03 2015-12-01 Method of treating disease by auricular anesthesia of cranial nerves ZA201508782B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361819023P 2013-05-03 2013-05-03
PCT/US2014/036855 WO2014179814A1 (en) 2013-05-03 2014-05-05 Method of treating disease by auricular anesthesia of cranial nerves

Publications (1)

Publication Number Publication Date
ZA201508782B true ZA201508782B (en) 2017-08-30

Family

ID=51844020

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA2015/08782A ZA201508782B (en) 2013-05-03 2015-12-01 Method of treating disease by auricular anesthesia of cranial nerves
ZA2018/03483A ZA201803483B (en) 2013-05-03 2018-05-25 Method of treating disease by auricular anesthesia of cranial nerves

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA2018/03483A ZA201803483B (en) 2013-05-03 2018-05-25 Method of treating disease by auricular anesthesia of cranial nerves

Country Status (17)

Country Link
US (4) US20140357686A1 (enExample)
EP (2) EP2991620B1 (enExample)
JP (3) JP6433985B2 (enExample)
KR (2) KR102086709B1 (enExample)
CN (2) CN105163718B (enExample)
AU (2) AU2014262148B2 (enExample)
CA (2) CA2910422C (enExample)
DK (1) DK2991620T3 (enExample)
ES (1) ES2823624T3 (enExample)
HK (1) HK1212230A1 (enExample)
IL (2) IL242339B (enExample)
MX (2) MX381106B (enExample)
MY (2) MY180310A (enExample)
RU (2) RU2687249C2 (enExample)
SG (1) SG11201508509XA (enExample)
WO (2) WO2014179814A1 (enExample)
ZA (2) ZA201508782B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2991620B1 (en) * 2013-05-03 2020-07-08 Crews, Thomas, M. Combinations of antipyrine and benzocaine for the treatment of diseases associated with a cranial nerve
WO2016137352A1 (ru) * 2015-02-26 2016-09-01 Общество С Ограниченной Ответственностью "Консорциум-Пик" Фармацевтическая композиция для лечения воспалительных заболеваний уха, способ ее получения и способ лечения указанной композицией
EP3509585B1 (en) 2016-09-07 2023-11-01 Glia, LLC Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves
US20220105052A1 (en) * 2016-12-26 2022-04-07 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
CN107789621A (zh) * 2017-12-15 2018-03-13 阜阳市平衡医疗保健器械有限公司 一种治疗头痛的药物及其配制方法
US11607275B2 (en) * 2019-05-20 2023-03-21 Medtronic Ireland Manufacturing Unlimited Company Selection of hypertensive patients for treatment with renal denervation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19524691A1 (de) * 1995-07-06 1997-01-09 Liedtke Pharmed Gmbh Methode und Zusammensetzung einer topischen Therapie von Innenohr und Labyrinth-Symptomen
RU2104056C1 (ru) * 1995-07-10 1998-02-10 Александр Александрович Ланцов Способ лечения периферических поражений лицевого нерва
JPH1094613A (ja) * 1996-08-02 1998-04-14 Mieko Sato 食欲調整用具
US6093417A (en) * 1999-01-11 2000-07-25 Advanced Medical Instruments Composition to treat ear disorders
ATE541565T1 (de) * 1999-05-27 2012-02-15 Khoury George F El Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
DE10322497A1 (de) * 2003-05-19 2004-12-09 Liedtke, Rainer K., Dr. Topisch pharmakologische Vorbeugung und Therapie der Hyperakusis
US8940321B2 (en) * 2003-12-12 2015-01-27 Otic Pharma Ltd. Compositions for treatment of ear disorders and methods of use thereof
US8755892B2 (en) * 2007-05-16 2014-06-17 Cardiac Pacemakers, Inc. Systems for stimulating neural targets
US20110208161A1 (en) * 2009-08-13 2011-08-25 Yehuda Ivri Intracochlear drug delivery to the central nervous system
US20120252730A1 (en) * 2009-09-03 2012-10-04 University Of Chicago Platelet aggregation inhibitors
CA2848730A1 (en) * 2011-09-15 2013-03-21 Yoseph Yaacobi Systems and methods for treating ear disorders
EP2991620B1 (en) * 2013-05-03 2020-07-08 Crews, Thomas, M. Combinations of antipyrine and benzocaine for the treatment of diseases associated with a cranial nerve

Also Published As

Publication number Publication date
SG11201508509XA (en) 2015-11-27
MY180310A (en) 2020-11-28
US20180360745A1 (en) 2018-12-20
MX2015015194A (es) 2016-02-11
IL259019A (en) 2018-06-28
KR20180088408A (ko) 2018-08-03
JP7512317B2 (ja) 2024-07-08
JP2018536709A (ja) 2018-12-13
RU2015148757A (ru) 2017-06-08
EP2991620A1 (en) 2016-03-09
CA3004160A1 (en) 2017-05-11
EP2991620B1 (en) 2020-07-08
AU2016349784B2 (en) 2019-06-06
US9968589B2 (en) 2018-05-15
CN108430470A (zh) 2018-08-21
EP3370716A4 (en) 2019-04-17
US20140357686A1 (en) 2014-12-04
US20220387307A1 (en) 2022-12-08
CN105163718B (zh) 2020-03-17
MX2018005625A (es) 2018-12-06
BR112018008893A8 (pt) 2019-02-26
HK1212230A1 (en) 2016-06-10
CA3004160C (en) 2023-03-14
JP6433985B2 (ja) 2018-12-05
NZ713746A (en) 2021-01-29
AU2014262148B2 (en) 2018-11-22
NZ742076A (en) 2024-12-20
EP2991620A4 (en) 2017-01-11
US20160051516A1 (en) 2016-02-25
KR102086709B1 (ko) 2020-03-09
EP3370716A1 (en) 2018-09-12
RU2701548C1 (ru) 2019-09-30
JP2016522819A (ja) 2016-08-04
MY196979A (en) 2023-05-16
IL259019B (en) 2021-06-30
MX390998B (es) 2025-03-21
KR102796310B1 (ko) 2025-04-16
RU2687249C2 (ru) 2019-05-08
MX381106B (es) 2025-03-04
CA2910422A1 (en) 2014-11-06
IL242339B (en) 2020-05-31
AU2014262148A1 (en) 2015-11-05
BR112018008893A2 (pt) 2018-11-06
AU2016349784A1 (en) 2018-05-17
ES2823624T3 (es) 2021-05-07
CN105163718A (zh) 2015-12-16
DK2991620T3 (da) 2020-10-12
JP2022065015A (ja) 2022-04-26
WO2017079270A1 (en) 2017-05-11
CA2910422C (en) 2022-09-27
ZA201803483B (en) 2019-08-28
US11123284B2 (en) 2021-09-21
WO2014179814A1 (en) 2014-11-06
KR20160003012A (ko) 2016-01-08

Similar Documents

Publication Publication Date Title
IL266648B (en) A method for treating Parkinson's disease
ZA201601024B (en) Methods and compositions for treating brain diseases
ZA201602839B (en) Methods of using interleukin-10 for treating diseases and disorders
PL2983787T3 (pl) Sposób leczenia zespołu stresu pourazowego
IL241134A0 (en) Method and system for treating neuromotor system dysfunction
ZA201803483B (en) Method of treating disease by auricular anesthesia of cranial nerves
EP2986306A4 (en) METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
IL240987A0 (en) Methods for treating solid tumors in children
IL244042A0 (en) A method for treating leiftic disease
PT2961426T (pt) Tratamento de transtornos do sistema nervoso central por administração intranasal de imunoglobulina g
IL245538A0 (en) Treatment methods for abnormal muscle activity
GB201308466D0 (en) Improved process for treatment of minewater
SMT201900542T1 (it) Metodi di trattamento dei disturbi del ciclo dell'urea
IL241096A0 (en) Treatment methods
SG10201802808SA (en) Method of treating ocular disorders
SG11201602010VA (en) Heat treatment method
GB201322778D0 (en) Method of treatment
GB201314882D0 (en) Method of treatment
IL241482B (en) A method for treating Parkinson's disease
GB201303721D0 (en) Compositions for treatment of sleep disorders